Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;11(10):837-42.

Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study

Aalie Torabizadeh  1 , Fatemeh Vahidroodsari  1 , Zakieh Ghorbanpour  1
Affiliations

Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study

Aalie Torabizadeh et al. Iran J Reprod Med. 2013 Oct.

Abstract

Background: Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during Assisted Reproductive Technology (ART) protocols. OHSS typically is a result of ovarian expression of vascular endothelial growth factor (VEGF) which increases vascular permeability.

Objective: Comparison of albumin and cabergoline in the prevention of OHSS.

Materials and methods: 95 high risk infertile women for OHSS (more than 20 follicles in both ovaries at day of Human Chorionic Gonadotropin (HCG) injection) were randomly divided into two groups. First group including 48 women received 10 unit intravenous albumin at starting oocyte retrieval, and second group including 47 women received 0.5 mg/day dopamine agonist (Cabergolin) at day of HCG injection till 8 days. The dosage of human Menopausal Gonadotropin (HMG) used, total number of follicles developed, number of oocytes retrieved, serum E2 concentrations during the luteal phase, development of ascites, number of embryos generated, clinical pregnancy rate, results of the in vitro fertilization-embryo transfer (IVF-ET) cycles and incidence and severity of any OHSS were evaluated.

Results: There was evidence of a statistically significant reduction in the incidence of OHSS in the cabergolin group (53.7%) versus albumin group (46.3%) (p=0.04). But there was no significant difference of a reduction in severe OHSS (p=0.62). There was no difference in clinical pregnancy rate too.

Conclusion: Administration of cabergolin can prevent incidence of OHSS and does not appear to effect on its severity.

Registration id in irct: IRCT138706281217N4.

Keywords: Albumin; Assistedreproductivetechnology(ART); Cabergolin; Ovarianhyperstimulationsyndrome (OHSS).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort flow diagram
See this image and copyright information in PMC

References

    1. Chen CD, Chen SU, Yang YS. Prevention and management of ovarian hyperstimulation syndrome. Best Pract Res Clin Obstet Gynaecol. 2012;26:817–827. - PubMed
    1. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod. 2000;15:1037–1042. - PubMed
    1. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010;94:389–400. - PubMed
    1. Gómez R, Simón C, Remohí J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats and this effect is prevented by receptor blockade. Endocrinology. 2002;143:4339–4348. - PubMed
    1. Albert C, Garrido N, Mercader A, Rao CV, Remohí J, Simón C, et al. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod. 2002;8:409–418. - PubMed

LinkOut - more resources